Patient characteristics and treatment of neovascular age-related macular degeneration in France: the LUEUR1 observational study

  • Salomon-Yves Cohen
  • Eric H. Souied
  • Michel Weber
  • Gérard Dupeyron
  • Gérard de Pouvourville
  • Michel Lievre
  • Anne Ponthieux
Retinal Disorders



Age-related macular degeneration is the primary cause of blindness in developed countries. Current treatments of this degenerative disease mainly include laser, photodynamic therapy with verteporfin and administration of anti-vascular endothelial growth factors. The LUEUR (LUcentis® En Utilisation Réelle) study is composed of a cross-sectional part (LUEUR1), which examined the current management of wet AMD in France, and a follow-up part (LUEUR2), which will assess the development of patients treated for wet AMD over 4 years. Here we describe the results of LUEUR1.


Patients with wet AMD were enrolled during a routine medical examination in LUEUR1, a cross-sectional, observational, prospective, multicentre study. Investigators recorded patient demographics, visual acuity, characteristics of wet AMD lesions, date of AMD diagnosis, comorbidities, previous treatments, treatments prescribed at inclusion, and low vision rehabilitation.


A total of 72 investigators recruited 1,019 patients with wet AMD, corresponding to 1,405 eyes affected by the disease. The mean age of patients was 78.7 ± 7.3 years. Most were female (62.3%) and non-smokers (66.9%). The mean visual acuity was 49.12 ± 24.18 Early Treatment Diabetic Retinopathy Study letters. Most eyes showed occult (52.8%) and subfoveal (84.6%) choroidal neovascularisation. Bilateral wet AMD affected 37.9% of patients. The median time since diagnosis was 12 months. Ranibizumab-based therapy (67.3%) and photodynamic therapy (29.8%) were the most frequent previous treatments. Prior to inclusion, 5.6% of patients had low vision rehabilitation. When a treatment was prescribed on the day of inclusion, it was most often ranibizumab (89.0% of all treatments at inclusion).


The results of this study illustrate the impact of anti-vascular endothelial growth factor therapies on the treatment of wet AMD in a real-life context. Specifically, ranibizumab-based therapy appears to have largely replaced laser photocoagulation and verteporfin-based photodynamic therapy.


Neovascularisation Epidemiology Retina Age-related macular degeneration Ranibizumab LUEUR 



age-related macular degeneration


choroidal neovascularisation


photodynamic therapy


vascular endothelial growth factor


Early Treatment Diabetic Retinopathy Study

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Salomon-Yves Cohen
    • 1
  • Eric H. Souied
    • 2
  • Michel Weber
    • 3
  • Gérard Dupeyron
    • 4
  • Gérard de Pouvourville
    • 5
  • Michel Lievre
    • 6
  • Anne Ponthieux
    • 7
  1. 1.Centre Ophtalmologique d’Imagerie et de LaserParisFrance
  2. 2.Faculté de Medecine Henri MondorCreteil University Eye ClinicCréteilFrance
  3. 3.Ophthalmology DepartmentHôtel-Dieu University HospitalNantes Cedex 1France
  4. 4.Ophthalmology DepartmentNimes University HospitalNîmes cedex 9France
  5. 5.Health Economics, ESSECCergy-PontoiseFrance
  6. 6.Clinical Pharmacology DepartmentLyon 1 University, Service de Pharmacologie Clinique, Faculté de MédecineLyonFrance
  7. 7.Novartis Pharma SASRueil MalmaisonFrance

Personalised recommendations